Classification and scoring systems in myelodysplastic syndromes: A retrospective analysis of 311 patients

Navarro, Isabel; Ruiz, Milton Artur; Cabello, A; Collado, Rosa; Ferrer, Rafael Alemany; Hueso, José Antonio; Martı́nez, Jesús; Miguel, Amparo; Orero, Maite; Pérez, Pedro Luis Hernández; Nolasco, Andreu; Carbonell, Félix

doi:10.1016/j.leukres.2005.11.015

Cited by 26 publications

(28 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The International Prognostic Scoring System (IPSS) divides patients into four distinct groups based on percentage of bone marrow blasts, cytogenetic abnormalities, and number of peripheral blood cytopenias [6]. The IPSS classification has been predictive of MDS survival in clinical studies [4,10,31,33,34], and has also proven useful in predicting outcome of secondary MDS. Details about previous treatment, cytogenetics, cell counts, and prognostic groupings such as IPSS (originally developed only for primary MDS) would be helpful in determining whether shortened survival among MDS cases with certain types of previous cancer is mediated by biologic effects resulting from cancer treatment regimens…”

Section: Years)mentioning

confidence: 99%

“…The prognosis of MDS is often poor, with overall survival reported as low as 10% in 10 years [1], and clinical observations suggest a worse prognosis for secondary than for primary MDS [2,3]. Most previous studies of survival among MDS patients have focused solely on primary MDS [4][5][6][7][8][9][10]. However, a large proportion of MDS cases arises from persons with a previous cancer diagnosis, therefore, a better understanding of the impact of previous cancers and their treatments on survival in MDS patients is of interest.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers

Roos

Deeg

Davis

2007

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

Section: Years)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers

Roos

Deeg

Davis

2007

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…Published papers have shown possible differences in biological features of MDS between patients from Western countries [21][22][23] and those from Asia. [24][25][26] Asian MDS patients are younger and have a much lower incidence of isolated 5q-syndrome.…”

Section: Discussionmentioning

confidence: 99%

A prospective multicenter observational study for decitabine treatment in Korean patients with myelodysplastic syndrome.

Lee¹,

Jang²,

Lee³

et al. 2010

JCO

View full text Add to dashboard Cite

BackgroundDecitabine was evaluated for its efficacy and safety in Korean patients with myelodysplastic syndrome with IPSS score of 0.5 or over. Design and MethodsDecitabine 20 mg/m 2 /day was given intravenously over one hour for five consecutive days every four weeks. The primary end point was overall response rate. ResultsA total of 101 patients were analyzed. The International Prognostic Scoring System risk category was Intermediate-2/High in 47.5%. A median of 5 courses (range 1-18) were delivered. The overall response rate was 55.4% (13 complete responses, one partial response, 23 marrow complete responses, and 19 hematologic improvements). Forty-eight patients (47.5%) showed some hematologic improvement. With a median follow-up duration of 478 days (range 69-595), median overall survival was 17.7 months. Patients who showed hematologic improvement had significantly longer overall survival than those who did not (19.2 vs. 15.9 months, P=0.006 by landmark analysis at six months). The difference in overall survival was evident in the Intermediate-2/High risk group but not in the Intermediate-1 risk group. The progressionfree survival and acute myeloid leukemia-free survival were 61.9% and 77.9% at one year, respectively. Among 489 assessable treatment courses, there were 97 fever episodes requiring intravenous antimicrobials. ConclusionsDecitabine treatment was feasible and effective in Korean patients with myelodysplastic syndrome, and the overall survival was significantly longer in patients showing hematologic improvement. (ClinicalTrials.gov Identifier: NCT01041846)

show abstract

“…We investigated the three factors raised by WPSS and our results showed that these factors had great prognostic correlations with OS of MDS patients either in univariate or Cox regression analysis. Many multi-center results proved that WHO classification can provide better prognosis of MDS than conventional FAB classification [5,8,9,12] after 2002. As the wide application of WHO classification, IPSS based on FAB classification has no longer been able to adapt the WHO classification well.…”

Section: Discussionmentioning

confidence: 99%

“…[7] defined a WHO-based prognostic scoring system (WPSS) including WHO subgroups, karyotype abnormalities categorized according to IPSS and transfusion requirement to predict survival and leukemia progression at any time during follow-up. Although many single-center analyses validated that the use of IPSS combination with WHO classification can improve the predictive value of overall survival of MDS [8,9] , the prognostic significance of WPSS has not been fully evaluated. In this study, 100 cases of de novo MDS patients from Tongji and Union Hospital of Tongji Medical College of Huazhong University of Science and Technology (Wuhan, China) were investigated to evaluate the significance of WPSS in prognosis of MDS.…”

Section: Introductionmentioning

confidence: 99%

Analysis of WHO-based Prognostic Scoring System (WPSS) of myelody-splastic syndrome and its comparison with international prognostic scoring system (IPSS) in 100 Chinese patients

Wei

Zhou

et al. 2009

Chin. J. Cancer Res.

View full text Add to dashboard Cite

Objective:The aims of this study were to assess the prognostic significance of WHO-based Prognostic Scoring System (WPSS) in myelodysplastic syndrome (MDS) from a single center institute and to compare WPSS with the international prognostic scoring system (IPSS).Methods: A total of 100 cases with de novo MDS were reviewed and their karyotypes were detected. All of them were followed up and classified according to IPSS and WPSS risk groups. SPSS 13.0 software was applied to deal with all the data. The statistical methods included Kaplan -Meier, Log-rank test and cox regression.Results: Multivariate cox regression analysis indicated that WHO Classification (P=0.0190), karyotype abnormalities categorized according to IPSS (P=0.0159) and red blood cell (RBC) transfusion (P=0.0009) were the three most important independent factors for predicting overall survival (OS) of MDS. WPSS and IPSS both had great capacity in predicting the OS of MDS at the time of diagnosis (P<0.0001). In time-dependent analysis, WPSS can predict the OS accurately in the following three years after diagnosis (P<0.0001), while IPSS failed to predict the OS 24 months after diagnosis (P=0.1094).Conclusion: Our single center results proved that WPSS is a dynamic prognostic system which can predict the OS of MDS patients at any time during the course of their disease. This time-dependent prognostic scoring system may replace the IPSS in the near future.

show abstract

Classification and scoring systems in myelodysplastic syndromes: A retrospective analysis of 311 patients

Cited by 26 publications

References 35 publications

A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers

A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers

A prospective multicenter observational study for decitabine treatment in Korean patients with myelodysplastic syndrome.

Analysis of WHO-based Prognostic Scoring System (WPSS) of myelody-splastic syndrome and its comparison with international prognostic scoring system (IPSS) in 100 Chinese patients

Contact Info

Product

Resources

About